Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, ...

In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise ...

Laurus Labs has seen a notable increase in its consensus analyst price target, which has risen from ₹724.14 to ₹815.86. This revision follows renewed analyst optimism, attributed largely to the ...

Revenue: INR1,570 crores, reflecting a 31% year-on-year growth. Gross Margin: 59%, an increase of more than 4% due to better product mix and process improvements. EBITDA: INR389 crores with a margin ...

LAURUSLABS surged on June 1. The stock opened at Rs 334.65, up over 2 per cent from its Wednesday's close of Rs 330.7 on the ...

JM Financial anticipates significant shifts in the MSCI India Standard Index. Laurus Labs and Biocon are flagged as ...

When Dr Satyanarayana Chava started Laurus Labs in 2007, he invested nearly Rs 60 crore of his own money into it. His confidence in its success was neither bravado nor bluster, but defined by his ...

JM said the price impact on inclusion names can play out due to active institutional positioning. Historical evidence ...

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs ...

Sharekhan had an interaction with Laurus Labs management and their commentary was positive, pointing towards a robust growth outlook. Laurus’ formulations business is on a strong growth footing, ...

Laurus Labs has received a tentative nod from the Food and Drug Administration for Dolutegravir 5 mg and 10 mg for pediatric ARV treatment. This pediatric drug administration through oral dispersible ...

Acquisition of Richcore to add new capabilities. Laurus has announced acquisition of 72% stake in Richcore Lifesciences for Rs 2.5 bn, valuing the business at ~6X FY2021 sales and 15X FY2021 EBITDA.